Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system

Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Tatsuya Takenouchi, Kenji Yokota, Hiroshi Uchi, Naoki Noma, Yasuhiro Nakamura, Jun Asai, Junji Kato, Susumu Fujiwara, Satoshi Fukushima, Jiro Uehara, Toshihiko Hoashi, Tatsuya Kaji, Taku Fujimura, Kenjiro Namikawa, Manabu Yoshioka, Naoki Murata, Dai Ogata & 13 others Kanako Matsuyama, Naohito Hatta, Yoshitsugu Shibayama, Toshiharu Fujiyama, Masashi Ishikawa, Daisuke Yamada, Akiko Kishi, Yoshiyuki Nakamura, Takatoshi Shimiauchi, Kazuyasu Fujii, Manabu Fujimoto, Hironobu Ihn, Norito Katoh

Research output: Contribution to journalArticle

Abstract

Background: The American Joint Committee on Cancer (AJCC) 8 th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. Objective: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. Methods: The AJCC 7 th and 8 th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8 th staging were selected. The Kaplan–Meier method was used to estimate disease-specific survival and relapse-free survival. Results: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7 th and 8 th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7 th and 8 th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA = 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID = none/6.5%. Conclusion: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7 th and 8 th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8 th Edition staging were completely different from the 7 th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively.

Original languageEnglish
JournalJournal of dermatological science
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Neoplasm Staging
Melanoma
Databases
Survival
Neoplasms
Recurrence
Population

Keywords

  • Epidemiology
  • Melanoma

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. / Fujisawa, Yasuhiro; Yoshikawa, Shusuke; Minagawa, Akane; Takenouchi, Tatsuya; Yokota, Kenji; Uchi, Hiroshi; Noma, Naoki; Nakamura, Yasuhiro; Asai, Jun; Kato, Junji; Fujiwara, Susumu; Fukushima, Satoshi; Uehara, Jiro; Hoashi, Toshihiko; Kaji, Tatsuya; Fujimura, Taku; Namikawa, Kenjiro; Yoshioka, Manabu; Murata, Naoki; Ogata, Dai; Matsuyama, Kanako; Hatta, Naohito; Shibayama, Yoshitsugu; Fujiyama, Toshiharu; Ishikawa, Masashi; Yamada, Daisuke; Kishi, Akiko; Nakamura, Yoshiyuki; Shimiauchi, Takatoshi; Fujii, Kazuyasu; Fujimoto, Manabu; Ihn, Hironobu; Katoh, Norito.

In: Journal of dermatological science, 01.01.2019.

Research output: Contribution to journalArticle

Fujisawa, Y, Yoshikawa, S, Minagawa, A, Takenouchi, T, Yokota, K, Uchi, H, Noma, N, Nakamura, Y, Asai, J, Kato, J, Fujiwara, S, Fukushima, S, Uehara, J, Hoashi, T, Kaji, T, Fujimura, T, Namikawa, K, Yoshioka, M, Murata, N, Ogata, D, Matsuyama, K, Hatta, N, Shibayama, Y, Fujiyama, T, Ishikawa, M, Yamada, D, Kishi, A, Nakamura, Y, Shimiauchi, T, Fujii, K, Fujimoto, M, Ihn, H & Katoh, N 2019, 'Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system', Journal of dermatological science. https://doi.org/10.1016/j.jdermsci.2019.04.003
Fujisawa, Yasuhiro ; Yoshikawa, Shusuke ; Minagawa, Akane ; Takenouchi, Tatsuya ; Yokota, Kenji ; Uchi, Hiroshi ; Noma, Naoki ; Nakamura, Yasuhiro ; Asai, Jun ; Kato, Junji ; Fujiwara, Susumu ; Fukushima, Satoshi ; Uehara, Jiro ; Hoashi, Toshihiko ; Kaji, Tatsuya ; Fujimura, Taku ; Namikawa, Kenjiro ; Yoshioka, Manabu ; Murata, Naoki ; Ogata, Dai ; Matsuyama, Kanako ; Hatta, Naohito ; Shibayama, Yoshitsugu ; Fujiyama, Toshiharu ; Ishikawa, Masashi ; Yamada, Daisuke ; Kishi, Akiko ; Nakamura, Yoshiyuki ; Shimiauchi, Takatoshi ; Fujii, Kazuyasu ; Fujimoto, Manabu ; Ihn, Hironobu ; Katoh, Norito. / Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. In: Journal of dermatological science. 2019.
@article{4eb7e23245fc4cf89d80606ec072c066,
title = "Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system",
abstract = "Background: The American Joint Committee on Cancer (AJCC) 8 th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. Objective: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. Methods: The AJCC 7 th and 8 th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8 th staging were selected. The Kaplan–Meier method was used to estimate disease-specific survival and relapse-free survival. Results: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7 th and 8 th Edition staging system were as follows: IA = 98.5{\%}/97.9{\%}; IB = 95.4{\%}/96.2{\%}; IIA = 94.2{\%}/94.1{\%}; IIB = 84.6{\%}/84.4{\%}; IIC = 72.2{\%}/72.2{\%}; IIIA = 76.2{\%}/87.5{\%}; IIIB = 60.7{\%}/72.6{\%}; IIIC = 42.0{\%}/55.3{\%} and IIID = none/26.0{\%}. The 5-year relapse-free survival according to the 7 th and 8 th Edition staging was as follows: IA = 94.5{\%}/92.7{\%}; IB = 85.4{\%}/85.3{\%}; IIA = 80.1{\%}/79.4{\%}; IIB = 71.4{\%}/70.6{\%}; IIC = 56.8{\%}/55.7{\%}; IIIA = 56.8{\%}/69.4{\%}; IIIB = 42.6{\%}/56.8{\%}; IIIC = 20.0{\%}/33.3{\%} and IIID = none/6.5{\%}. Conclusion: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7 th and 8 th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8 th Edition staging were completely different from the 7 th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively.",
keywords = "Epidemiology, Melanoma",
author = "Yasuhiro Fujisawa and Shusuke Yoshikawa and Akane Minagawa and Tatsuya Takenouchi and Kenji Yokota and Hiroshi Uchi and Naoki Noma and Yasuhiro Nakamura and Jun Asai and Junji Kato and Susumu Fujiwara and Satoshi Fukushima and Jiro Uehara and Toshihiko Hoashi and Tatsuya Kaji and Taku Fujimura and Kenjiro Namikawa and Manabu Yoshioka and Naoki Murata and Dai Ogata and Kanako Matsuyama and Naohito Hatta and Yoshitsugu Shibayama and Toshiharu Fujiyama and Masashi Ishikawa and Daisuke Yamada and Akiko Kishi and Yoshiyuki Nakamura and Takatoshi Shimiauchi and Kazuyasu Fujii and Manabu Fujimoto and Hironobu Ihn and Norito Katoh",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jdermsci.2019.04.003",
language = "English",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system

AU - Fujisawa, Yasuhiro

AU - Yoshikawa, Shusuke

AU - Minagawa, Akane

AU - Takenouchi, Tatsuya

AU - Yokota, Kenji

AU - Uchi, Hiroshi

AU - Noma, Naoki

AU - Nakamura, Yasuhiro

AU - Asai, Jun

AU - Kato, Junji

AU - Fujiwara, Susumu

AU - Fukushima, Satoshi

AU - Uehara, Jiro

AU - Hoashi, Toshihiko

AU - Kaji, Tatsuya

AU - Fujimura, Taku

AU - Namikawa, Kenjiro

AU - Yoshioka, Manabu

AU - Murata, Naoki

AU - Ogata, Dai

AU - Matsuyama, Kanako

AU - Hatta, Naohito

AU - Shibayama, Yoshitsugu

AU - Fujiyama, Toshiharu

AU - Ishikawa, Masashi

AU - Yamada, Daisuke

AU - Kishi, Akiko

AU - Nakamura, Yoshiyuki

AU - Shimiauchi, Takatoshi

AU - Fujii, Kazuyasu

AU - Fujimoto, Manabu

AU - Ihn, Hironobu

AU - Katoh, Norito

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The American Joint Committee on Cancer (AJCC) 8 th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. Objective: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. Methods: The AJCC 7 th and 8 th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8 th staging were selected. The Kaplan–Meier method was used to estimate disease-specific survival and relapse-free survival. Results: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7 th and 8 th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7 th and 8 th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA = 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID = none/6.5%. Conclusion: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7 th and 8 th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8 th Edition staging were completely different from the 7 th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively.

AB - Background: The American Joint Committee on Cancer (AJCC) 8 th Edition Cancer Staging System was implemented in 2018; however, it has not been validated in an Asian melanoma population. Objective: The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. Methods: The AJCC 7 th and 8 th Editions were used for TNM classification of patients in a database established by the Japanese Melanoma Study Group. Patient data with sufficient information to be applicable to the AJCC 8 th staging were selected. The Kaplan–Meier method was used to estimate disease-specific survival and relapse-free survival. Results: In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7 th and 8 th Edition staging system were as follows: IA = 98.5%/97.9%; IB = 95.4%/96.2%; IIA = 94.2%/94.1%; IIB = 84.6%/84.4%; IIC = 72.2%/72.2%; IIIA = 76.2%/87.5%; IIIB = 60.7%/72.6%; IIIC = 42.0%/55.3% and IIID = none/26.0%. The 5-year relapse-free survival according to the 7 th and 8 th Edition staging was as follows: IA = 94.5%/92.7%; IB = 85.4%/85.3%; IIA = 80.1%/79.4%; IIB = 71.4%/70.6%; IIC = 56.8%/55.7%; IIIA = 56.8%/69.4%; IIIB = 42.6%/56.8%; IIIC = 20.0%/33.3% and IIID = none/6.5%. Conclusion: The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7 th and 8 th Edition systems, we should be careful in managing Stage III disease since the survival curves of the 8 th Edition staging were completely different from the 7 th Edition. Moreover, our results indicate that adjuvant therapies for Stage IIB and IIC should be developed, since the relapse-free survival for these stages were equivalent to Stage IIIA and IIIB, respectively.

KW - Epidemiology

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=85064573692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064573692&partnerID=8YFLogxK

U2 - 10.1016/j.jdermsci.2019.04.003

DO - 10.1016/j.jdermsci.2019.04.003

M3 - Article

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

ER -